Abstract:The toxicity potential and inadequate bioavailability of antiretroviral therapy restrict their effectiveness in completely eradicating HIV-1 from viral reservoirs, as the drugs encounter difficulties in accessing these reservoirs. This study presents a combinatorial D-α-tocopheryl polyethylene glycol succinate (TPGS)-decorated nano-structured lipid carrier of Etravirine (ETR) and Darunavir Ethanolate (DRVE) that was formulated, optimized, and characterized to achieve synergistic effects against HIV-1 infection. The effectiveness of the combinatorial approach was evaluated by in silico studies, and their docking score and free binding energy showed that both drugs demonstrate synergistic effects against their respective enzymes. The cellular research of ED (ETR and DRVE) in TMZ-b1 cell lines also showed that the best ratio of ETR and DRVE (1:6.5 μg/mL) produced a combined effect. The formulation, termed ED-TPGS-NLCs, underwent optimization using central composite rotational design (CCRD) through a modified emulsification process, followed by characterization based on globule size, polydispersity index (PDI), percentage entrapment efficiency, percentage drug loading, and transmission electron microscopy (TEM) analysis. In vitro release studies demonstrated a notable improvement of drug release from the optimized lipid nanosystem, conforming to the Korsmeyer-Peppas kinetics model. Besides, the in-vitro studies, the intestinal permeation enhancement study, the intestinal depth analysis, and the pharmacokinetic assessment of the optimized formulation in Wistar rats were performed to improve permeation and increase plasma drug concentration. ED-TPGS-NLCs also stopped HIV-1 infection in TMZ-b1 cell lines by 50%, and the lowest concentration needed to do this was about 58 times lower than purified ED suspension. These studies ensure that ED-TPGS-NLCs were taken up due to the formation of chylomicrons and inhibit the p-gp efflux system by TPGS and solutol to inhibit the first-pass hepatic metabolism, which helps to improve the intestinal permeation and enhance plasma drug concentration, leading to enhanced oral bioavailability of ED. Hence, the improved bioavailability of ED in the nanoformulation also enhanced the anti-retroviral efficacy and improved the safety margins of ED-TPGS-NLCs. These findings can also reduce the side effects of high doses of antiretroviral drugs. Graphical abstract Download : Download high-res image (366KB) Download : Download full-size image

Co-Delivery of Hiv-1 Entry Inhibitor and Nonnucleoside Reverse Transcriptase Inhibitor Shuttled by Nanoparticles: Cocktail Therapeutic Strategy for Antiviral Therapy

A nanoparticle-encapsulated non-nucleoside reverse-transcriptase inhibitor with enhanced anti-HIV-1 activity and prolonged circulation time in plasma.

Synthesis, Nanosizing and in Vitro Drug Release of A Novel Anti-Hiv Polymeric Prodrug: Chitosan-O-Isopropyl-5 '-O-d4t Monophosphate Conjugate

Recent Developments of Nanotherapeutics for Targeted and Long-Acting, Combination HIV Chemotherapy

Treg Cell Evaluation in Patients with Acquired Immune Deficiency Syndrome with Poor Immune Reconstitution and Human Immunodeficiency Virus-Infected Treg Cell Prevention by Polymeric Nanoparticle Drug Delivery System.

A novel formulation enabled transformation of 3-HIV drugs tenofovir-lamivudine-dolutegravir from short-acting to long-acting all-in-one injectable

D-α-Tocopheryl Polyethylene Glycol Succinate-decorated dual drug-loaded lipidic nanocarriers: A Strategic approach for targeting lymphatic uptake and p-gp efflux modulation to enhance oral bioavailability in HIV-1 viral reservoirs

Enfuvirtide-Protoporphyrin IX Dual-Loaded Liposomes: In Vitro Evidence of Synergy against HIV-1 Entry into Cells

A “Two-Birds-One-Stone” Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region

Design Strategies for Long-Acting Anti-Hiv Pharmaceuticals.

Boronic Acid-Containing Diarylpyrimidine Derivatives As Novel HIV-1 NNRTIs: Design, Synthesis and Biological Evaluation

Systems Approach to Targeted and Long-Acting HIV/AIDS Therapy

Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood (vol 28, pg 2625, 2014)

Anti-HIV Drug-Combination Nanoparticles Enhance Plasma Drug Exposure Duration As Well As Triple-Drug Combination Levels in Cells Within Lymph Nodes and Blood in Primates.

Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation.

Antiretroviral Drugs-Loaded Nanoparticles Fabricated by Dispersion Polymerization with Potential for HIV/AIDS Treatment

Nanodrug Formulations to Enhance HIV Drug Exposure in Lymphoid Tissues and Cells: Clinical Significance and Potential Impact on Treatment and Eradication of HIV/AIDS

Synergistic effect resulting from combinations of a bifunctional HIV-1 antagonist with antiretroviral drugs.

A novel preventive strategy against HIV-1 infection: combinatorial use of inhibitors targeting the nucleocapsid and fusion proteins

Preparation and Characterization of Anti-Hiv Nanodrug Targeted to Microfold Cell of Gut-Associated Lymphoid Tissue

Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance.